Opthalmic compositions comprising F6H8

Patent metadata

Field	Value
Publication number	US-11896559-B2
Application number	US-201816753701-A
Country	US
Kind code	B2
Filing date	Oct 3, 2018
Priority date	Oct 4, 2017
Publication date	Feb 13, 2024
Grant date	Feb 13, 2024

Abstract

The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.

First claim

The invention claimed is:

1. A method of increasing tear film thickness and/or increasing the lipid layer thickness, wherein the method comprises the steps of: (a) administering to the eye of a patient in need thereof an amount of an ophthalmic composition consisting of a mixture of F(CF 2 ) 6 (CH 2 ) 8 H and 2-perfluorohexyloctane, optionally wherein the amount is effective to enrich an ophthalmic tissue in F(CF 2 ) 6 (CH 2 ) 8 H, and optionally (b) delayed release of F(CF 2 ) 6 (CH 2 ) 8 H from the enriched ophthalmic tissue;
wherein the ophthalmic composition is administered to the surface of the cornea and/or the conjunctiva in the form of liquid eye drops; and
wherein the patient suffers from keratoconjunctivitis sicca (dry eye disease).

2. The method according to claim 1 , wherein the method is effective to enrich an ophthalmic tissue in F(CF 2 ) 6 (CH 2 ) 8 H.

3. The method of claim 2 , wherein the ophthalmic tissue enriched in F(CF 2 ) 6 (CH 2 ) 8 H is the palpebral conjunctiva, the cornea, the Meibomian glands, the lacrimal glands and/or the bulbar conjunctiva.

4. The method of claim 3 , wherein the Meibomian glands comprise 0.0001 to 0.05 wt % of F(CF 2 ) 6 (CH 2 ) 8 H.

5. The method of claim 1 , wherein the composition consists of F(CF 2 ) 6 (CH 2 ) 8 H and up to 3 wt. % of 2-perfluorohexyloctane, based on the total weight of the composition.

6. The method of claim 5 , wherein the composition consists of F(CF 2 ) 6 (CH 2 ) 8 H and up to 1 wt.% of 2-perfluorohexyloctane, based on the total weight of the composition.

7. The method according to claim 1 , wherein the patient suffers from Meibomian gland dysfunction, and/or the keratoconjunctivitis sicca (dry eye disease) is due to Meibomian gland dysfunction.

8. The method according to claim 7 , wherein the patient is non-responsive to traditional physical methods of treating Meibomian Gland Dysfunction and/or is non-responsive to treatment with aqueous ophthalmic eye drop compositions.

9. The method according to claim 1 , wherein the composition is administered in a dose of a single drop per eye less than four times per day.

10. The method according to claim 1 , wherein the composition is administered in a dose of a single drop of 10-12 μl per eye two times per day.

11. The method of claim 1 , wherein the patient is characterized by at least 2 of the criteria selected from the group consisting of:
(i) a total ocular surface disease index (OSDI) of higher than 25;
(ii) a total corneal fluorescein staining (NEI scale) between 4 and 11;
(iii) a Schirmer's Test I greater than 5 mm; and
(iv) an MGD score of higher than 3.

12. The method according to claim 1 , wherein the method is effective in treating (reducing) simultaneously the ocular surface damage of one or more corneal regions, and the symptoms of dryness of the patient, wherein the patient suffers from Meibomian gland dysfunction, and/or the keratoconjunctivitis sicca (dry eye disease) is due to Meibomian gland dysfunction.

13. The method according to claim 12 , wherein the ocular surface damage of one or more corneal regions is selected from the group consisting of:
(i) ocular surface damage of the total corneal region;
(ii) ocular surface damage of the central corneal region;
(iii) ocular surface damage of the nasal corneal region;
(iv) ocular surface damage of the temporal corneal region; and
(v) combinations thereof.

14. The method according to claim 12 , wherein the one or more symptoms of dryness are selected from the group consisting of:
(i) severity of dryness;
(ii) blurred vision;
(iii) sensitivity of light;
(iv) frequency of dryness;
(v) awareness of dryness; and
(vi) any combination thereof.

15. The method according to claim 1 , wherein the ophthalmic composition is administered in a dose of a single drop of 10-11 μl per eye two to four times per day.

16. The method according to claim 1 , wherein the method is a method of increasing the lipid layer thickness, and wherein the method is effective to increase lipid layer thickness immediately after drop instillation and/or continuously over a treatment period of 4 weeks.

17. The method according to claim 1 , wherein the patients are suffering from mild to moderate keratoconjunctivitis sicca (dry eye disease).

18. The method according to claim 1 , wherein the tear film thickness is increased after a single dose of the composition.

19. The method according to claim 1 , wherein the tear film thickness is increased within ten minutes of administration of a dose of the composition.

20. The method according to claim 1 , wherein the composition is administered for at least two weeks and the lipid layer thickness is improved after 2 weeks of treatment.

Assignees

• Novaliq Gmbh

Inventors

• Günther Bernhard
• LÖSCHER Frank
• Voss Hartmut
• Krösser Sonja
• Eickhoff Kirsten
• Willen Daniela
• Beier Markus
• Schlüter Thomas

Classifications

• A61P27/02

  Ophthalmic agents · CPC title

• A61P27/04

  Artificial tears; Irrigation solutions · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K31/02 Primary

  Halogenated hydrocarbons · CPC title